Caroline Y. Chen

Caroline Y. Chen

Auto-generated profile, based on publicly available information

Caroline Y. Chen

Jonsson Comprehensive Cancer Center, UCLA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Nature
Verified
Journal Article
Closed access
PDF file
FNFarshad Nassiri
Farshad Nassiri
JLJeff Liu
Jeff Liu
VPVikas Patil
Vikas Patil
YMYasin Mamatjan
Yasin Mamatjan
JWJustin Z. Wang
Justin Z. Wang
GZGelareh Zadeh
Gelareh Zadeh

13 November 2020 in Case Reports in Rheumatology
Verified
Journal Article
Open access
JAJafar Al-Mondhiry
Jafar Al-Mondhiry
CCCaroline Y. Chen
Caroline Y. Chen
MRMichael H. Rosove
Michael H. Rosove
Systemic lupus erythematosus may present with several distinct autoimmune phenomena simultaneously. We report a patient presenting with three serious hematologic disorders: thrombotic thrombocytopenic purpura, catastrophic antiphospholipid syndrome, and warm-type IgG red cell autoantibodies. The case is an example of the complex clinical nature of lupus and the importance of accurately identifying individual complications in order to optimize management.

8 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CCCaroline Y. Chen
Caroline Y. Chen
JAJaron Arbet
Jaron Arbet
CZChenghao Zhu
Chenghao Zhu
JOJieun Oh
Jieun Oh
PBPaul C. Boutros
Paul C. Boutros
Background: Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related mortality, with an increasing incidence and dismal 10% survival at 5 years despite best available care. PDAC is characterized by low tumour cellularity, recurrent driver mutation alterations, and substantial inter and intra-tumoural heterogeneity. The influence of individual genetic features such as sex and ancestry on tumour heterogeneity remains poorly understood. Methods: We assembled a cohort of PDAC across five datasets for a total of 7,527 tumours. Measures of genomic instability were assessed across sex and ancestry on a global level (SNV density and percent genome altered by copy number events), and at a gene level for recurrent events. KRAS variant frequencies, ploidy and mRNA abundance were also evaluated. Ancestry was assigned using ADMIXTURE from germline genotypes where available, and patient reported otherwise. Results: We observed ancestry-specific mutation patterns in global point mutation density, with higher SNV burden in African PDAC tumours and lower SNV burden in Asian PDAC tumours as compared to European tumours. We also identified an ancestry bias in the driver gene, GNAS , in which driver SNVs in GNAS was detected more frequently in those of Asian ancestry, and less frequently in those of African ancestry. No sex- or ancestry-associations were found for KRAS , but individual KRAS variants showed a trend towards ancestry-related variation. Conclusions: These findings demonstrate that ancestry contributes to the genomic heterogeneity of PDAC, shaping both global and gene-specific mutation patterns. This work underscores the importance of including diverse ancestries in PDAC molecular profiling efforts which may inform the development of tailored molecular diagnostics and targeted therapies.